QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AUPH

QT81Aurinia Pharmaceuticals Inc.
NASDAQ·Healthcare·Biotechnology·Canada
Latest market price
16.46
+0.32+1.98%
OverviewShort InterestFilings
AUPHQT81Aurinia Pharmaceuticals Inc.·NASDAQ
OverviewShort InterestFilings
16.46+1.98%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E7.16EPS (ttm)
2.16
Insider Own15.68%
Shs Outstand128.60M
Perf Week3.85%
Market Cap2.08BForward P/E13.32EPS next Y1.24Insider Trans1.33%Shs Float-Perf Month5.85%
Enterprise Value2.10BPEG0.01EPS next Q0.21Inst Own-Short Float-Perf Quarter16.99%
Income289.76MP/S6.96EPS this Y-55.56%Inst Trans-Short Ratio-Perf Half Y3.85%
Sales298.29MP/B3.76EPS next Y28.75%ROA41.19%Short Interest-Perf YTD3.20%
Book/sh4.42P/C12.88EPS next 5Y20.66%ROE64.48%52W High16.88 -2.49%Perf Year108.09%
Cash/sh2.95P/FCF12.54EPS past 3/5Y-ROIC18.99%52W Low7.29 125.79%Perf 3Y-
Dividend Est.-EV/EBITDA13.00Sales past 3/5Y28.30% 41.44%Gross Margin89.74%Volatility1.82% 2.47%Perf 5Y-
Dividend TTM-EV/Sales7.05EPS Y/Y TTM2190.08%Oper. Margin41.73%ATR (14)0.52Perf 10Y-
Dividend Ex-Date-Quick Ratio5.01Sales Y/Y TTM26.81%Profit Margin99.97%RSI (14)61.12Recom2.67
Dividend Gr. 3/5Y-Current Ratio5.55EPS Q/Q56.25%SMA204.76%Beta0.93Target Price12.60
Payout0.00%Debt/Eq0.12Sales Q/Q25.81%SMA504.29%Rel Volume0.99Prev Close16.14
Employees130LT Debt/Eq0.10EarningsJul 30SMA20012.87%Avg Volume1.18MPrice16.46
IPO DateSep 03, 2014Option/ShortYes / YesEPS/Sales Surpr.38.89% 1.30%Net Debt/EBITDA0.17Volume1,169,658Change1.98%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-03-25DowngradeLeerink PartnersOutperform → Market Perform$16
Nov-07-25UpgradeJefferiesHold → Buy
Nov-05-25DowngradeRBC CapitalOutperform → Sector Perform$15
Sep-06-24ReiteratedH.C. WainwrightBuy$26 → $13
May-02-24ReiteratedJefferies$6.00
Jan-04-23ReiteratedRBC CapitalOutperform$22 → $11
Nov-04-22DowngradeOppenheimerOutperform → Perform
Aug-09-22ReiteratedH.C. WainwrightBuy$30 → $26
Aug-08-22ReiteratedOppenheimerOutperform$13
May-05-22ReiteratedH.C. WainwrightBuy$30
Latest News
Jun-16-26
Jun-16-2609:10AM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum RatingChartMill
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue298283235
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A313328
Gross Profit268250207
Selling, General and Administrative Excl. Other103102172
Research and Development333321
Other Operating Expense71019
Operating Income124105-5
Interest Expense945
Unusual Expense
———
Non-Operating Income (Expense)-18-14-17
Net Income Before Taxes1341147
Income Taxes-164-1732
Consolidated Net Income2992876
Net Income From Continuing Operations2992876
Net Income2992876
EPS (Recurring)2.242.140.04
EPS (Basic, Before Extraordinaries)2.242.140.04
EPS (Diluted)2.162.070.04
EBITDA16212832
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio7.627.71—
Price To Sales Ratio7.297.55—
Gross Margin89.9388.3488.09
Operating Margin41.6137.10-2.13
Net Margin100.34101.412.55
Shares Outstanding132134143
Market Capitalization2,1732,137—
Operating Lease Expense
———
Insider Trading Volume
$17.01$15.93$14.86$13.79$12.71● Close Price0.00M3.40M6.79M10.19M13.59MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
TANG KEVINChief Executive OfficerJun 02 '26Buy15.28206,0053,147,75613,044,106Jun 02 12:00 AM
TANG KEVINChief Executive OfficerJun 01 '26Buy15.28343,6205,250,52012,838,101Jun 02 12:00 AM
TANG KEVINChief Executive OfficerMay 29 '26Buy15.31264,9814,056,95112,494,481Jun 02 12:00 AM
TANG KEVINDirectorMar 03 '26Buy14.22184,2082,619,43812,229,500Mar 03 12:00 AM
TANG KEVINDirectorMar 02 '26Buy14.26199,3532,842,83312,045,292Mar 03 12:00 AM
TANG KEVINDirectorFeb 27 '26Buy13.99516,4397,226,53511,845,939Mar 03 12:00 AM
TANG KEVINDirectorAug 05 '25Buy11.68200,0002,336,00011,329,500Aug 05 12:00 AM
TANG KEVINDirectorAug 04 '25Buy11.34100,0001,134,00011,129,500Aug 05 12:00 AM
TANG KEVINDirectorAug 01 '25Buy10.121,000,00010,120,00011,029,500Aug 05 12:00 AM
Keenan GregChief Medical OfficerAug 01 '25Sale10.5020,000210,000133,484Aug 05 12:00 AM
Keenan GregChief Medical OfficerMar 07 '25Sale8.238,30568,350153,484Mar 07 12:00 AM
Miller Joseph MChief Financial OfficerMar 04 '25Sale7.9256,154444,740577,361Mar 04 12:00 AM
TANG KEVINDirectorMar 04 '25Buy7.96748,0385,953,30410,029,500Mar 04 12:00 AM
Greenleaf PeterChief Executive OfficerMar 04 '25Sale7.92164,9471,306,3801,788,945Mar 04 12:00 AM
Donley Matthew MaxwellChief Operating OfficerMar 04 '25Sale7.9258,991467,209680,465Mar 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR